|
業務類別
|
Biotechnology |
|
業務概覽
|
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products foroncology. |
| 公司地址
| 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404 |
| 電話號碼
| +1 650 473-7700 |
| 傳真號碼
| +1 650 473-7750 |
| 公司網頁
| https://www.geron.com |
| 員工數量
| 258 |
| Ms. Michelle J. Robertson |
Executive Vice President, Finance, Chief Financial Officer, Principal Accounting Officer and Treasurer |
美元 540.80K |
02/03/2026 |
| Mr. Harout Semerjian |
Director, President and Chief Executive Officer |
-- |
02/03/2026 |
| Mr. Ahmed ElNawawi |
Executive Vice President and Chief Commercial Officer |
-- |
02/03/2026 |
| Dr. Joseph Emile Eid, M.D. |
Executive Vice President, Research and Development |
美元 93.75K |
02/03/2026 |
|
|
| Dr. V. Bryan Lawlis, PhD |
Independent Director |
02/03/2026 |
| Dr. Robert Jay Spiegel, F.A.C.P. |
Independent Director |
02/03/2026 |
| Mr. John F. McDonald |
Independent Director |
02/03/2026 |
| Dr. Susan M. Molineaux, PhD |
Independent Director |
02/03/2026 |
| Ms. Dawn Carter Bir |
Director |
02/03/2026 |
| Ms. Elizabeth G. O’Farrell |
Chairman of the Board and Lead Independent Director |
02/03/2026 |
| Mr. Harout Semerjian |
Director, President and Chief Executive Officer |
02/03/2026 |
|
|
|
|
